Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data CytoDyn Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
FY2026
Revenue
0
0.27
0
Cost of revenue
0.05
Gross profit
0.21
Research and development
20.2
38.2
42.5
52.6
53.4
27
2.63
7.24
General and administrative
6.76
7.34
12.1
20
34.3
44.3
17.1
10.8
7.26
7.45
Operating expenses
27.3
45.9
55.9
74.6
Operating income
-27.3
-45.9
-55.9
-74.6
-105
-145
-40.6
-18.1
9.66
-38.6
Interest expense
0.61
5.92
3.31
18.2
71.9
65.4
39.2
31.8
Interest income
0.02
0
0
0.01
0
0.22
0.57
0.26
Pre-tax income
-25.8
-50.1
-59
-140
-176
-211
-79.8
-49.8
3.75
-42.7
Income tax
0
0
-2.83
0
0
0
0
0
0
0
Net income
-25.8
-50.1
-56.2
-140
-176
-211
-79.8
-49.8
3.75
-42.7
EBITDA
-27
-45.6
-54.6
-72.6
-103
-145
-40.4
-18
9.68
-38.6
EPS, basic
-0.33
-0.30
-0.31
-0.10
-0.05
0.00
-0.03
EPS, diluted
-0.33
-0.30
-0.31
-0.10
-0.05
0.00
-0.03
Shares, basic (weighted)
138
175
272
421
588
677
837
970
1,206
1,289
Shares, diluted (weighted)
138
175
272
421
588
677
837
970
1,243
1,289
Balance sheet
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
FY2026
Cash and equivalents
1.78
1.23
2.61
14.3
33.9
4.23
2.54
3.11
11.9
11.9
Inventory
19.1
93.5
0
0
Other current assets
0.21
0.23
0.11
0.5
0.62
5.2
1.17
0.46
0.25
0.75
Total current assets
6.12
3.32
5.37
36.8
36.1
10.5
10.8
10.8
17.9
13.9
Property, plant and equipment
0.02
0.01
0.03
0.06
0.13
0.07
Lease right-of-use assets
0
0.18
0.71
0.54
0.4
0.26
0.13
0.07
Intangible assets
1.92
1.57
15.5
13.5
1.65
0.13
Other non-current assets
0.74
0.49
0.32
0.17
0.1
Total assets
8.06
4.9
20.9
50.5
132
29.2
11.3
11.1
18
14
Accounts payable
4.28
15.8
16.2
29.5
65.9
68
62.7
29.6
14.7
13.2
Accrued liabilities
0.64
0.06
0.16
1.72
4.01
1.52
0.34
0.21
0.28
0.92
Total current liabilities
6.14
16.7
26.9
44.5
153
123
120
84.2
70.5
53.7
Lease liabilities
0
0.06
0.55
0.42
0.28
0.14
0
0.05
Other non-current liabilities
43.6
43.6
43.6
Total liabilities
9.16
18.1
29.8
53
153
124
121
128
114
124
Total debt
0
42.2
42.2
45.7
45
45.4
38.3
Paid-in capital
122
160
225
372
532
671
731
774
790
819
Retained earnings
-123
-173
-234
-375
-554
-766
-842
-892
-888
-930
Treasury stock
-0
-0
-0
0
0
Shareholders' equity
-1.1
-13.2
-8.91
-2.48
-21
-94.4
-110
-117
-96
-110
Total equity
-1.1
-13.2
-8.91
-2.48
-21
-94.4
-110
-117
-96
-110
Total liabilities and equity
8.06
4.9
20.9
50.5
132
29.2
11.3
11.1
18
14
Shares outstanding
149
217
329
519
626
720
919
1,059
1,249
1,374
Cash flow statement
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
FY2026
Net income
-25.8
-50.1
-56.2
-140
-176
-211
-79.8
-49.8
3.75
-42.7
Depreciation and amortization
0.37
0.36
1.25
2.03
1.8
0.78
0.18
0.03
0.02
0.02
Stock-based compensation
1.2
1.29
3.39
6.55
10.4
6.24
4.28
2.42
1.61
1.63
Deferred income tax
0
0
-2.83
0
0
0
0
Change in inventory
-19.1
-79.4
2.06
Change in payables
1.5
12.4
1.74
19
53
-2.71
-3.1
10.8
-11.3
17.9
Cash from operations
-26.7
-29.9
-50.5
-68.8
-118
-77.7
-25.1
-11
-8.77
-17.3
Capital expenditures
-0.01
0
-0.03
-0.04
-0.12
Cash from investing
-0.01
0
-0.05
-0.04
-0.12
0
0
Debt repaid
-2.19
-0.95
Stock issued
8.99
8.99
5.6
1.84
0.39
0.11
0.9
Cash from financing
18.9
29.4
52.7
79.7
137
48
29.9
11.7
10.9
17.2
Net change in cash
-7.87
-0.54
2.24
10.8
19.7
-29.7
4.82
0.77
2.09
-0.05
Free cash flow
-26.7
-29.9
-50.5
-68.8
-118
Interest paid
0
0.01
0
0.24
0.15
0.06
0.02
0.05
0.03
0.02
Key metrics
Worked out from the statements above. Latest values use fiscal 2026. Valuation uses the share price of $0.21 on September 28, 2026.
Profitability
Metric
Value
How it is calculated
Return on assets (ROA)
-266.7%
Net income / average total assets.
Growth
Metric
Value
How it is calculated
Operating income growth, 1y
-499.3%
Operating income vs the same period a year earlier. Only from a positive base.
EBITDA growth, 1y
-498.4%
EBITDA vs the same period a year earlier. Only from a positive base.
Net income growth, 1y
-1,240.0%
Net income vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y
-22.6%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
7.4%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-36.2%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
3.7%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
15.5%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
17.0%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
0.26x
Current assets / current liabilities.
Quick ratio
0.22x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.22x
(Cash + short-term investments) / current liabilities.
Debt / assets
274.4%
Total debt / total assets.
Liabilities / assets
885.2%
Total liabilities / total assets.
Net debt
$26.5M
Total debt - cash - short-term investments. Negative means more cash than debt.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
EPS, basic
-$0.03
Net income per basic share, as reported (split-adjusted).
Operating cash flow per share
-$0.01
Cash from operations / diluted weighted shares.
Book value per share
-$0.08
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
Earnings yield
-14.7%
Net income / market cap (the inverse of P/E).
Was CytoDyn Inc. profitable in fiscal 2026?
No. It reported a net loss of $42.7M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.